Baseline | Post-treatment | |||||
---|---|---|---|---|---|---|
Bamako | Koulikoro | Ségou | Bamako | Koulikoro | Ségou | |
(n = 273) | (n = 153) | (n = 427) | (n = 273) | (n = 153) | (n = 427) | |
Parasitology | ||||||
% Uninfected | 45.05 (< 0.001)a | 14.38 (< 0.001)b | 8.90 (< 0.001)c | 64.10 (< 0.001)d ** | 32.68 (0.010)e ** | 40.05 (< 0.001)f ** |
% Infected with S. haematobium | 43.96 (< 0.001)a | 3.92 (< 0.001)b | 57.38 (< 0.001) c | 26.37 (< 0.001)d ** | 5.23 (< 0.001)e | 35.36 (0.011) f ** |
% Infected with S. mansoni | 1.10 (< 0.001)a | 24.84 (< 0.001)b | 4.22 (0.007)c | 4.03 (< 0.001)d ** | 40.52 (< 0.001)e ** | 14.05 (< 0.001)f ** |
% Co-infected | 9.89 (< 0.001)a | 56.86 (< 0.001)b | 29.51 (< 0.001)c | 5.49 (< 0.001)d ** | 21.57 (0.002)e ** | 10.54 (0.013) f ** |
% Heavy S. haematobium infections | 13.19 (0.040) a | 7.19 (< 0.001) b | 39.58 (< 0.001) | 2.20 (0.161) c ** | 0.65 (< 0.001) e ** | 7.73 (< 0.001) f ** |
% Heavy S. mansoni infections | 0.73 (< 0.001) | 22.88 (0.005) | 12.41 (< 0.001) | 0.00 (< 0.001) | 10.46 (0.003) ** | 2.81 (< 0.001) ** |
Liver Pathology as assessed by ultrasound (US) examination | ||||||
% with abnormal liver image patterns | 0.37 (0.316)a | 0.00 (< 0.001)b | 12.18 (< 0.001)c | 0.37 (0.316)d | 0.00 (< 0.001)e | 12.88 (< 0.001)f |
% with portal hypertension (as determined by positive PVD scores) | 0.73 (0.585)a | 1.31 (< 0.001)b | 9.60 (< 0.001)c | 5.49 (0.013)d ** | 13.07 (0.076)e ** | 7.73 (0.237)f |
% with hepatomegaly (as determined by positive PSL scores from US) | 0.37 (0.701)a | 0.65 (0.085)b | 2.34 (0.085)c | 0.00 (0.316)d | 0.65 (0.545)e | 0.23 (0.317)f ** |
Liver + spleen pathology as assessed by clinical examination | ||||||
% with hepatomegaly as assessed by MSL>2 cm | 0.00 (0.316)a | 0.65 (< 0.001)b | 9.84 (< 0.001)c | 0.00 (0.080)d | 1.96 (0.291)e | 0.70 (0.082)f ** |
% with hepatomegaly as assessed by MCL>2 cm | 0.00 (0.316)a | 0.65 (< 0.001)b | 8.67 (< 0.001)c | 0.00 (0.080)d | 1.96 (0.291)e | 0.70 (0.082)f ** |
% with splenomegaly as assessed by MCL>2 cm | 0.73 (< 0.001)a | 12.42 (< 0.001)b | 27.17 (< 0.001)c | 0.00 (0.023)d | 3.27 (0.009)e ** | 8.43 (< 0.001)f ** |
% with splenomegaly as assessed by MAL>2 cm | 0.73 (< 0.001)a | 8.50 (< 0.001)b | 25.06 (< 0.001)c | 0.00 (0.043)d | 2.61 (0.010)e ** | 7.26 (< 0.001)f ** |
Bladder Pathology as assessed by US examination | ||||||
Bladder pathology (as determined by positive global scores from US) | 8.42 (0.194)a | 5.23 (< 0.001)b | 22.95 (< 0.001)c | 22.34 (0.057)d ** | 15.03 (< 0.001)e ** | 3.98 (< 0.001)f ** |